Current Report Filing (8-k)
October 13 2022 - 08:25AM
Edgar (US Regulatory)
0001812173 false 0001812173 2022-10-12
2022-10-12 0001812173
RBOT:ClassCommonStockParValue0.0001PerShareMember 2022-10-12
2022-10-12 0001812173
RBOT:WarrantsToPurchaseOneShareOfClassCommonStockEachAtExercisePriceOf11.50PerShareMember
2022-10-12 2022-10-12 iso4217:USD xbrli:shares iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported):
October 13, 2022
VICARIOUS SURGICAL INC.
(Exact
name of registrant as specified in its charter)
|
Delaware |
|
001-39384 |
|
87-2678169 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification
No.)
|
|
78 Fourth Avenue |
|
|
|
Waltham,
Massachusetts |
|
02451 |
|
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (617)
868-1700
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on
which registered |
|
Class A common stock, par value $0.0001 per
share |
|
RBOT |
|
The New York Stock Exchange |
|
Warrants to purchase one share of Class A common stock, each at an
exercise price of $11.50 per share |
|
RBOT WS |
|
The New York Stock Exchange |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
Item
7.01 Regulation FD Disclosure.
On October 13, 2022, Vicarious Surgical Inc. (the “Company”) issued
a press release announcing that the Company will host a
Demonstration Day of its Beta 2 surgical robot prototype for
investors and analysts starting at 11:00 a.m. ET on Tuesday,
December 6, 2022, at its Waltham, MA headquarters. Further details
will be released closer to the event. Due to limited capacity,
in-person attendance is by invitation only. The event will be
broadcast live over the internet and will be accessible on the
investor relations section of the Company’s website,
https://investor.vicarioussurgical.com. A copy of the press release
is furnished as Exhibit 99.1 hereto.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| |
VICARIOUS
SURGICAL INC. |
|
|
|
|
| |
By: |
/s/
Adam Sachs |
| |
Name: |
Adam
Sachs |
| |
Title: |
President
and Chief Executive Officer |
|
Date:
October 13, 2022 |
2
D8 (NYSE:DEH)
Historical Stock Chart
From Dec 2022 to Jan 2023
D8 (NYSE:DEH)
Historical Stock Chart
From Jan 2022 to Jan 2023
